New research: “Raynaud’s syndrome is a common dysautonomia where cold increases vascular tone of distal arteries causing vasoconstriction and hypoxia... Our results indicate Raynaud’s is related to vascular function mediated by adrenergic signaling through ADRA2A.“
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
The α2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud’s syndrome
medRxiv - The Preprint Server for Health Sciences
www.medrxiv.org
October 13, 2023 at 3:09 AM
New research: “Raynaud’s syndrome is a common dysautonomia where cold increases vascular tone of distal arteries causing vasoconstriction and hypoxia... Our results indicate Raynaud’s is related to vascular function mediated by adrenergic signaling through ADRA2A.“
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Then, we tested the C-fiber nociceptors component. Ensemble composition changed only modestly across an array of skin stimuli. In contrast, representation of cutaneous vs visceral pressure diverged strongly, with Adra2a+ C-fibers dominating response to bladder and colorectal distension. 4/8
December 14, 2025 at 6:30 PM
Then, we tested the C-fiber nociceptors component. Ensemble composition changed only modestly across an array of skin stimuli. In contrast, representation of cutaneous vs visceral pressure diverged strongly, with Adra2a+ C-fibers dominating response to bladder and colorectal distension. 4/8
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org
For data drop announcements via email sign up at evebio.org
For data drop announcements via email sign up at evebio.org
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products. Data Release 1 now live.
data.evebio.org
February 10, 2025 at 7:27 PM
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org
For data drop announcements via email sign up at evebio.org
For data drop announcements via email sign up at evebio.org
#research #ADRA2A #Yohimbine
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.: doi.org/10.1021/acs....
@iocbprague.bsky.social
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.: doi.org/10.1021/acs....
@iocbprague.bsky.social
July 2, 2024 at 9:28 AM
#research #ADRA2A #Yohimbine
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.: doi.org/10.1021/acs....
@iocbprague.bsky.social
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.: doi.org/10.1021/acs....
@iocbprague.bsky.social
RRIDs were included in this in bioRxiv paper. RRIDs improve reproducibility in scientific research. #STMpublishing #BetterScience #accelerateopenscience
A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation
Read the full paper: A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation
doi.org
April 22, 2026 at 7:03 AM
RRIDs were included in this in bioRxiv paper. RRIDs improve reproducibility in scientific research. #STMpublishing #BetterScience #accelerateopenscience
RRIDs were included in this None paper. Thanks for making your methods matter! #RRID #RRID #reproducibility
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
doi.org
August 16, 2025 at 7:00 AM
RRIDs were included in this None paper. Thanks for making your methods matter! #RRID #RRID #reproducibility
#RaynaudsSyndrome GWAS
GTEx-eQTL scRNAseq ISH->
ADRA2A/α2 Adrenergic receptors->
Expressed in distal coronary/skin arteriolar #SmoothMuscleCell
⏫SMC contractility under cold stress (28°C)
SNP CRISPR to modulate transcript level
#CellGenomics 2024
www.sciencedirect.com/science/arti...
GTEx-eQTL scRNAseq ISH->
ADRA2A/α2 Adrenergic receptors->
Expressed in distal coronary/skin arteriolar #SmoothMuscleCell
⏫SMC contractility under cold stress (28°C)
SNP CRISPR to modulate transcript level
#CellGenomics 2024
www.sciencedirect.com/science/arti...
September 1, 2024 at 11:05 PM
#RaynaudsSyndrome GWAS
GTEx-eQTL scRNAseq ISH->
ADRA2A/α2 Adrenergic receptors->
Expressed in distal coronary/skin arteriolar #SmoothMuscleCell
⏫SMC contractility under cold stress (28°C)
SNP CRISPR to modulate transcript level
#CellGenomics 2024
www.sciencedirect.com/science/arti...
GTEx-eQTL scRNAseq ISH->
ADRA2A/α2 Adrenergic receptors->
Expressed in distal coronary/skin arteriolar #SmoothMuscleCell
⏫SMC contractility under cold stress (28°C)
SNP CRISPR to modulate transcript level
#CellGenomics 2024
www.sciencedirect.com/science/arti...
Thanks! I just received my first Rx, and it says it’s also used to treat high blood pressure. I have POTS, meaning i’m prone to low blood pressure. What should i be watchful for, if anything?
Also, fyi, apparently i “have an anamoly on the ADRA2A gene that makes you less responsive to guanfacine”
Also, fyi, apparently i “have an anamoly on the ADRA2A gene that makes you less responsive to guanfacine”
June 6, 2024 at 10:21 PM
Thanks! I just received my first Rx, and it says it’s also used to treat high blood pressure. I have POTS, meaning i’m prone to low blood pressure. What should i be watchful for, if anything?
Also, fyi, apparently i “have an anamoly on the ADRA2A gene that makes you less responsive to guanfacine”
Also, fyi, apparently i “have an anamoly on the ADRA2A gene that makes you less responsive to guanfacine”
🧪🩺🧬🖥️ Direct link to the paper: www.nature.com/articles/s41...
ADRA2A and IRX1 are putative risk genes for Raynaud’s phenomenon - Nature Communications
Raynaud’s phenomenon is a common vasospastic disorder, but the genetic origins of the condition are not well understood. Here, the authors find common genetic variants associated with Raynaud’s ph...
www.nature.com
October 16, 2023 at 6:55 PM
🧪🩺🧬🖥️ Direct link to the paper: www.nature.com/articles/s41...
#ecology #publichealth
Key genes:
MAOA, MGLL, ADRA2A, RPN2, GF1R, CTSD.
Prolactin pathways.
Strong affinity of BPA for MGLL.
The contribution of
phenolic endocrine-disrupting chemicals
bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP)
to breast cancer risk
.
www.nature.com/articles/s41...
Key genes:
MAOA, MGLL, ADRA2A, RPN2, GF1R, CTSD.
Prolactin pathways.
Strong affinity of BPA for MGLL.
The contribution of
phenolic endocrine-disrupting chemicals
bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP)
to breast cancer risk
.
www.nature.com/articles/s41...
The contribution of phenolic endocrine-disrupting chemicals to breast cancer risk: A comprehensive bioinformatics analysis - Scientific Reports
Bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP) are common environmental phenolic endocrine disruptors and widely used industrial chemicals that have garnered significant attention due to th...
www.nature.com
March 9, 2026 at 7:41 AM
#ecology #publichealth
Key genes:
MAOA, MGLL, ADRA2A, RPN2, GF1R, CTSD.
Prolactin pathways.
Strong affinity of BPA for MGLL.
The contribution of
phenolic endocrine-disrupting chemicals
bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP)
to breast cancer risk
.
www.nature.com/articles/s41...
Key genes:
MAOA, MGLL, ADRA2A, RPN2, GF1R, CTSD.
Prolactin pathways.
Strong affinity of BPA for MGLL.
The contribution of
phenolic endocrine-disrupting chemicals
bisphenol A (BPA), nonylphenol (NP), and octylphenol (OP)
to breast cancer risk
.
www.nature.com/articles/s41...
GLP-1を産生しているL細胞はアドレナリン受容体持っている らしい(Adra2a)。交感神経のノルアドニューロンに制御を受けているらしい。細胞内の反応のカスケードとしてはAdra2aの活性→CaMKIIのリン酸化阻害→GLP-1の分泌抑制。
July 17, 2024 at 3:39 AM
GLP-1を産生しているL細胞はアドレナリン受容体持っている らしい(Adra2a)。交感神経のノルアドニューロンに制御を受けているらしい。細胞内の反応のカスケードとしてはAdra2aの活性→CaMKIIのリン酸化阻害→GLP-1の分泌抑制。
"Indeed, we demonstrate that BEST4/CA7+ cells generate robust CFTR-mediated fluid efflux when stimulated with bacterial diarrhea-causing toxins and find the norepinephrine-ADRA2A axis as a potential mechanism in blocking BEST4/CA7+ cell-mediated fluid secretion. Our observations identify a […]
Original post on mastodon.social
mastodon.social
February 26, 2025 at 9:19 AM
"Indeed, we demonstrate that BEST4/CA7+ cells generate robust CFTR-mediated fluid efflux when stimulated with bacterial diarrhea-causing toxins and find the norepinephrine-ADRA2A axis as a potential mechanism in blocking BEST4/CA7+ cell-mediated fluid secretion. Our observations identify a […]
The alpha-2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud's syndrome https://www.medrxiv.org/content/10.1101/2023.10.04.23296526v1
The alpha-2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud's syndrome https://www.medrxiv.org/content/10.1101/2023.10.04.23296526v1
Raynaud's syndrome is a common dysautonomia where exposure to cold increases the vascular tone of di
www.medrxiv.org
October 5, 2023 at 11:40 PM
The alpha-2A-adrenergic receptor (ADRA2A) modulates susceptibility to Raynaud's syndrome https://www.medrxiv.org/content/10.1101/2023.10.04.23296526v1
Checking ADRA2A in our @amaticahealth cohort and it looks like a subgroup is high and low.
Which matches as not all ME/CFS patients respond the same.
Some actually show decreases in ADRA2A after exercise.
This diversity suggests different CDR profiles across patients.
Which matches as not all ME/CFS patients respond the same.
Some actually show decreases in ADRA2A after exercise.
This diversity suggests different CDR profiles across patients.
September 18, 2025 at 3:29 PM
Checking ADRA2A in our @amaticahealth cohort and it looks like a subgroup is high and low.
Which matches as not all ME/CFS patients respond the same.
Some actually show decreases in ADRA2A after exercise.
This diversity suggests different CDR profiles across patients.
Which matches as not all ME/CFS patients respond the same.
Some actually show decreases in ADRA2A after exercise.
This diversity suggests different CDR profiles across patients.
In most ME/CFS patients, exercise causes sharp increases in mRNA for:
- P2RX4 / P2RX5 (purinergic receptors)
- TRPV1 (pain receptor)
- ADRA2A (adrenergic receptor)
These genes are linked to pain, fatigue, and stress signals.
- P2RX4 / P2RX5 (purinergic receptors)
- TRPV1 (pain receptor)
- ADRA2A (adrenergic receptor)
These genes are linked to pain, fatigue, and stress signals.
September 18, 2025 at 3:29 PM
In most ME/CFS patients, exercise causes sharp increases in mRNA for:
- P2RX4 / P2RX5 (purinergic receptors)
- TRPV1 (pain receptor)
- ADRA2A (adrenergic receptor)
These genes are linked to pain, fatigue, and stress signals.
- P2RX4 / P2RX5 (purinergic receptors)
- TRPV1 (pain receptor)
- ADRA2A (adrenergic receptor)
These genes are linked to pain, fatigue, and stress signals.
#ENVB Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
https://www.stocktitan.net/news/ENVB/enveric-biosciences-unveils-evm401-series-of-compounds-with-new-u-s-30xwpegwru0s.html
https://www.stocktitan.net/news/ENVB/enveric-biosciences-unveils-evm401-series-of-compounds-with-new-u-s-30xwpegwru0s.html
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
Enveric Biosciences (NASDAQ: ENVB) has secured U.S. Patent No. 12,195,439 for its new EVM401 Series of mescaline derivative compounds. The patent, issued on January 14, 2025, covers 'Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives.'Preliminary testing shows these compounds demonstrate unique brain receptor modulation patterns, potentially interacting with:α2A adrenergic receptor (ADRA2A) - helpful for opioid withdrawal and ADHD5-HT2C receptor - target for neuropsychiatric diseases, substance use disorders, anxiety and depressionDopamine transporter (DAT) - important for substance use disorder treatmentWhile the company's main focus remains on the IND application for EB-003, this patent aims to expand their pipeline of non-hallucinogenic molecules for treating addiction and neuropsychiatric disorders.
www.stocktitan.net
February 25, 2025 at 6:30 PM
#ENVB Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
https://www.stocktitan.net/news/ENVB/enveric-biosciences-unveils-evm401-series-of-compounds-with-new-u-s-30xwpegwru0s.html
https://www.stocktitan.net/news/ENVB/enveric-biosciences-unveils-evm401-series-of-compounds-with-new-u-s-30xwpegwru0s.html
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classica
www.biorxiv.org
March 13, 2024 at 3:55 PM
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
#research #drugdesign #ADRA2Aantagonist
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.:
pubs.acs.org/doi/10.1021/...
@iocbprague.bsky.social
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.:
pubs.acs.org/doi/10.1021/...
@iocbprague.bsky.social
July 28, 2024 at 6:01 PM
#research #drugdesign #ADRA2Aantagonist
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.:
pubs.acs.org/doi/10.1021/...
@iocbprague.bsky.social
Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine (Mertlíková-Kaiserová, Janeba) - J. Med. Chem.:
pubs.acs.org/doi/10.1021/...
@iocbprague.bsky.social
A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation https://www.biorxiv.org/content/10.64898/2026.04.14.712766v1
April 17, 2026 at 5:15 PM
A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation https://www.biorxiv.org/content/10.64898/2026.04.14.712766v1
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classica
www.biorxiv.org
March 13, 2024 at 3:55 PM
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer https://www.biorxiv.org/content/10.1101/2024.03.12.584316v1
A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation https://www.biorxiv.org/content/10.64898/2026.04.14.712766v1
April 17, 2026 at 5:15 PM
A Novel Conditional Adra2a-Knockout Mouse Line Reveals Cell-specific Contributions to Specific Dimensions of Sedation https://www.biorxiv.org/content/10.64898/2026.04.14.712766v1
In their recent study, they found that ADRA2A/rs3750625/AC polymorphism may serve as a potential risk factor for #stress_related #bipolardisorder (doi.org/10.1016/j.ja...).
4/7
4/7
Redirecting
doi.org
April 18, 2025 at 2:38 PM
In their recent study, they found that ADRA2A/rs3750625/AC polymorphism may serve as a potential risk factor for #stress_related #bipolardisorder (doi.org/10.1016/j.ja...).
4/7
4/7